Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Aripiprazole lauroxil - Alkermes

Drug Profile

Aripiprazole lauroxil - Alkermes

Alternative Names: ALNCD; ALKS-9070; ALKS-9072; Aripiprazole Lauroxil NanoCrystal® Dispersion; ARISTADA; ARISTADA INITIO

Latest Information Update: 12 Mar 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Alkermes
  • Developer Alkermes plc
  • Class Antipsychotics; Chlorobenzenes; Ethers; Piperazines; Quinolines; Small molecules
  • Mechanism of Action Dopamine D2 receptor agonists; Serotonin 1A receptor agonists; Serotonin 2A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Schizophrenia

Most Recent Events

  • 01 Mar 2021 Alkermes has patent protection for aripiprazole lauroxil in USA before March 2021
  • 31 Dec 2019 Alkermes has multiple patent protection for aripiprazole in USA
  • 10 Apr 2019 Top-line safety and efficacy data from the phase III ALPINE trial in Schizophrenia released by Alkermes
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top